NCT01395316已完成4 期
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 8
- 主要终点
- Diffusion and Myelin Fraction Water Changes on Magnetic Resonance Imaging (MRI)
研究概览
简要总结
The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.
详细描述
To identify specific changes in T cell subsets and functions in Relapsing Remitting Multiple Sclerosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Alemtuzumab
Experimental
Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
干预措施: Alemtuzumab (Drug)
结局指标
主要结局
Diffusion and Myelin Fraction Water Changes on Magnetic Resonance Imaging (MRI)
时间窗: Baseline to Month 24
Changes in normal appearing white matter from baseline through month 24. The MRI is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.
次要结局
未报告次要终点
研究者
相似试验
Unknown
不适用
The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis PatientsMultiple SclerosisNCT03193086Glostrup University Hospital, Copenhagen35
撤回
1 期
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple SclerosisMultiple SclerosisNCT03983252Brigham and Women's Hospital10
终止
2 期
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCLPeripheral T-Cell LymphomaNCT00441025Mahidol University4
Unknown
3 期
Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis PatientsMultiple SclerosisNCT01333358Central Texas Neurology Consultants30
终止
2 期
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)LeukemiaNCT01191749M.D. Anderson Cancer Center7